| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00455 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | 本月底法定/註冊股本總額： HKD 400,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 天大藥業有限公司 呈交日期: 2026 ...

Core Insights - Tian Da Group has announced a dual-driven strategy focusing on "pharmaceutical health + fine phosphorus chemical" to enhance its industrial layout in Yunnan, marking a new phase of collaborative development and upgrade [1][5] Group Strategy - The company plans to deepen its pharmaceutical health industry layout in Yunnan, leveraging the region's unique biological resources as a key support for Tian Da Pharmaceutical's development [3] - Tian Da Pharmaceutical will implement a quality management system called "Tian Da Standard" to ensure product quality from the source of traditional Chinese medicine to the consumer end, with increased systematic investment in local medicinal materials [3] Product Development - The product matrix of Tian Da Pharmaceutical covers critical therapeutic areas such as cardiovascular, pediatrics, respiratory, anti-infection, and anti-tumor, with established brands like "He Gu" and "Tuo Kang" [3] - The company aims to promote high-quality products and services originating from Yunnan to national and global markets through its online and offline health service platform, "Tian Da Pavilion" [3] Phosphorus Chemical Industry - The fine phosphorus chemical sector will also be developed, with plans to invest in high-value-added projects based on the Xundian phosphorus mine, targeting the creation of a billion-level industrial cluster to assist in the transformation and upgrading of Yunnan's local industry [5] Commitment to Health - The chairman emphasized that the motto "Your health is a big deal for Tian Da" reflects the company's commitment to transforming Yunnan's ecological and resource advantages into high-quality health products and industrial momentum [5]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 天大藥業有限公司 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00455 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | 本月底法定/註冊股本總額： HKD 400,000,000 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 本月底法定/註冊股本總額： HKD 400,000,000 | 截至月份: | | --- | | 2025年10月31日 | | 狀態: | | 新提交 | 致：香港交易及結算所有限公司 公司名稱: 天大藥業有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00455 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,000,00 ...

本月底法定/註冊股本總額： HKD 400,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 天大藥業有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00455 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 4,000,000,000 | HKD | | 0 ...

(Stock Code ⫍֍ջ⽚厍455) NOTIFICATION LETTER 通知信函 Dear Non-registered Holder(s) (Note 1) , 29 September 2025 Tianda Pharmaceuticals Limited (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") (Incorporated in the Cayman Islands with limited liability) 䢼ᑠ㟜ᕎ⟲ෑ〾՟ᆕ⒦̅ᕘ㡍Վ܉䢽 Notes: 各位非登記股東 （附註1） ： 天大藥業有限公司（「本公司」） － 中期報告2025（「本次公司通訊」）之刊發通知 本公司的本次公司通訊之中、英文版本已分別上載於本公司網站( http://www.tiandapharma.com ) 及香港聯合交易所有限公司（「聯交所」）之網站 ( www.hkexnews.hk ) （「網站版本」）。本公司建議 閣下閱覽本公司本次公司通 ...

The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at http://www.tiandapharma.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corporate Communication and all future Corporate Communications (Note) . NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, 29 Sept ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: 2025年8月31日 | | --- | | 狀態: 新提交 | 本月底法定/註冊股本總額： HKD 400,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 致：香港交易及結算所有限公司 公司名稱: 天大藥業有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00455 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 4,000,000,000 | HKD | | 0.1 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | ...

Group 1 - The company reported revenue of HKD 136.6 million for the six months ending June 30, 2025, compared to HKD 156.1 million for the same period in 2024 [1] - The loss attributable to shareholders increased from HKD 27.2 million in the previous interim period to HKD 33.5 million in the current interim period [1] - The board of directors decided not to declare an interim dividend for the six months ending June 30, 2025, consistent with the previous year [1]

Group 1 - Tian Da Pharmaceutical (00455.HK) announced the resignation of Feng Quanming as a non-executive director due to other work commitments, effective from August 29, 2025 [1] - The company further announced the appointment of Zhu Haomiao as a non-executive director, also effective from August 29, 2025 [1]